Driving Patient-Centric Research: TrialX Highlights Upcoming AI Innovations in Clinical Trials at Patients as Partners Europe
Key Highlights of the 9th Annual Patients as Partners Europe Conference
- Patient Engagement is Evolving from Centricity to Integration: The conversation has shifted from simply including patients to fully integrating their voices and experiences across every stage of clinical research.
- Patient Experience Data is Shaping Development: Real-world insights from patients are being used to assess tolerability, refine protocols, and guide more effective and patient-friendly trial designs.
- Diversity and Inclusion Remain a Priority: The industry is focused on developing recruitment strategies that ensure clinical trials are inclusive and reflective of real-world populations.
- Actionable Insights and Regulatory Alignment Drive Progress: Turning patient feedback into measurable change, while aligning with evolving Health Technology Assessment (HTA) and regulatory expectations, is essential to advancing sustainable clinical development.
At the 9th Annual Patients as Partners Europe conference, industry leaders gathered to champion patient-centric clinical research. This flagship event sparked powerful conversations and collaborations focused on accelerating drug development through meaningful patient engagement. As executive sponsors, we proudly highlighted our upcoming AI-driven patient recruitment solutions, connected with attendees, and explored new partnerships to advance innovation in patient-centered trials.
TrialX Executive Chairman, Eric Sandor on the Agenda Session
Our Executive Chairman, Eric Sandor shared insights on use of AI in enhancing patient recruitment and shared how we are leveraging AI to improve clinical trial accessibility and patient-centricity. Eric’s talk focused on how AI is helping:
He emphasized both the current applications and the evolving future of AI in empowering patients to discover clinical trials more effectively. He explained how TrialX is personalizing the trial-matching process for patients using AI:
“The TrialX system will automatically generate questions to help narrow down those trials. The AI will decide what questions to ask the patient that will help narrow the field. It’s very much like the game ‘Guess Who’… you eliminate half of the field.”
He also highlighted the importance of simplifying medical language in clinical trial listings to improve accessibility for patients:
“We’ve translated the trial listings into US eighth grade English… This isn’t just a straightforward translation. It’s a recursive approach using AI to summarize, to simplify, to check the accuracy… and to focus on the key points that a patient actually wants to understand.”
Looking toward future integrations, Eric emphasized how TrialX is working to embed trial discovery into clinical workflows:
“…at the point of care with the patient, based on their EHR data… the doctor will get an alert [if the patient qualifies for a trial]. That kind of alert could be a really powerful solution to the awareness problem.”
He also underlined the growing role of personalization, particularly through AI and data-driven engagement:
“As our trials become geared around this patient genotype, phenotype… it really changes things dramatically across the R&D life cycle….We’ve got to think about personalization as a theme of how we interact with every patient, both for recruitment and for engagement.”
TrialX Solutions for Patient-Centric Global Clinical Trials
Trusted by 2 of the Top 5 Pharma companies, our award-winning platform, AI powered patient recruitment management platform helps patients find relevant studies quickly, while keeping them informed and engaged. At the heart of our presence at the conference was our suite of AI-driven tools designed to make clinical trials more accessible and efficient:
- Patient Recruitment Management Platform: A comprehensive solution featuring study website builders, pre-screeners and real-time analytics to standardize and streamline patient recruitment.
- Clinical Trial Finder: AI-powered guided search, personalized matching, and easy connect features simplify trial discovery, addressing recruitment inefficiencies that delay 86% of studies.
- Diversity & Inclusion Initiatives: Our partnerships with organizations like Reflections Collective, the Michael J. Fox Foundation and Let’s Win Pancreatic Cancer enhance representation and accessibility, including bilingual support for underserved communities.
- Remote Data Collection Platform: Enables virtual participation, real-time data capture, and seamless engagement via SMS, push notifications, and emails—reducing access barriers and improving retention rates.
Industry Insights & Key Takeaways
Experts from leading pharmaceutical companies—including Sanofi, Pfizer, Novo Nordisk, Regeneron, Johnson & Johnson, GSK, Boehringer Ingelheim, Lundbeck, AstraZeneca, Roche and more—came together with patient advocacy groups to address critical issues shaping the future of clinical research. Discussions centered on integrating patient-informed research, patient preferences in decentralized trials, advancing health equity and inclusivity, and evolving approaches to patient experience data. Participants explored actionable strategies for turning insights into impact, demonstrating the value of engagement, reducing trial burden through innovative technologies, and meeting regulatory expectations around patient involvement in drug development.
The conference opened with a compelling call to action: go beyond traditional notions of patient centricity and embed patient engagement across every stage of the clinical development lifecycle. Throughout the sessions, it became clear that the R&D ecosystem is evolving to treat patient partnership not just as a value, but as a measurable driver of medical progress. Victoria DiBiaso, Global Head, Patient Informed Development & Health Value Translation at Sanofi, shared a powerful perspective on this evolution, urging a shift from placing patients at the center to fully integrating their insights across the drug development continuum—from discovery science to market access. Her message emphasized the need for sustainable, system-wide engagement strategies that deliver better outcomes for all stakeholders.
The importance of inclusive engagement was underscored by the recognition of The Reflections Collective as a Fierce DEI Awards Finalist for Community Engagement and Outreach. Reflections is transforming how research connects with communities through art, storytelling, and technology. By amplifying underrepresented voices and co-creating access pathways with local leaders and advocates, this initiative is accelerating more inclusive and responsive clinical trials. TrialX is proud to support Reflections through our AI powered clinical trial finder tool, helping more patients access research that matters to them.
The 9th Annual Patients as Partners Europe Conference reinforced a central theme: patients must be active collaborators in clinical research—not just participants. At TrialX, we’re committed to driving this vision forward by leveraging AI to make trials more inclusive, accessible, and patient-centric. We look forward to continuing these conversations—and seeing you all next year!
